29,817 results match your criteria Alcoholic Fatty Liver

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.

Hepatology 2022 May 21. Epub 2022 May 21.

Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Background: Cholestasis is associated with disease severity and worse outcome in coronavirus disease of 2019 (COVID-19). Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection have been described.

Methods: Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were included. Read More

View Article and Full-Text PDF

[Efficacy of newly developed food for special dietary use in the diet of patients with non-alcoholic steatohepatitis].

Vopr Pitan 2022 14;91(2):31-42. Epub 2022 Mar 14.

Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation.

Although diet plays a leading role in treatment of non-alcoholic fatty disease (and, in particular, non-alcoholic steatohepatitis), specialized foods for the treatment of these patients have not yet been developed. of the study was to assess efficacy of the food for special dietary use (FSDU) in patients with non-alcoholic steatohepatitis. . Read More

View Article and Full-Text PDF

Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver.

Cell Mol Immunol 2022 May 20. Epub 2022 May 20.

State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.

Obesity is a major risk factor for cancers including hepatocellular carcinoma (HCC) that develops from a background of non-alcoholic fatty liver disease (NAFLD). Hypercholesterolemia is a common comorbidity of obesity. Although cholesterol biosynthesis mainly occurs in the liver, its role in HCC development of obese people remains obscure. Read More

View Article and Full-Text PDF

Exogenous administration of unacylated ghrelin attenuates hepatic steatosis in high-fat diet-fed rats by modulating glucose homeostasis, lipogenesis, oxidative stress, and endoplasmic reticulum stress.

Samah Alharbi

Biomed Pharmacother 2022 May 17;151:113095. Epub 2022 May 17.

Physiology Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. Electronic address:

Low levels of unacylated ghrelin (UAG) and a higher ratio of acylated ghrelin (AG)/UAG in obesity are associated with non-alcoholic fatty liver disease (NAFLD). This study tested the potential protective effect of increased circulatory levels of UAG by exogenous UAG administration on hepatic steatosis in high-fat diet (HFD)-fed rats and investigated some possible mechanisms. Rats were divided (n = 6/group) as low fat diet (LFD), LFD + UAG (200 mg/kg), HFD, HFD + UAG (50, 100, or 200 mg/kg). Read More

View Article and Full-Text PDF

Concentrated fish oil ameliorates non-alcoholic fatty liver disease by regulating fibroblast growth factor 21-adiponectin axis.

Nutrition 2022 Mar 23;99-100:111659. Epub 2022 Mar 23.

Institute of Nutrition & Health, Qingdao University, Qingdao, China; School of Public Health, Qingdao University, Qingdao, China; Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, Australia; Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China. Electronic address:

Objectives: The fibroblast growth factor 21 (FGF21)-adiponectin axis participates in energy hemostasis and obesity-related syndrome. The present study aimed to investigate whether concentrated fish oil (FO) intervention could alleviate non-alcoholic fatty liver disease (NAFLD) via the regulation of the FGF21-adiponectin axis.

Methods: In a randomized controlled trial, 61 patients with NAFLD, age 55. Read More

View Article and Full-Text PDF

Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy.

Clin Transplant 2022 May 20:e14714. Epub 2022 May 20.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Background & Aims: Non-alcoholic steatohepatitis (NASH) is associated with metabolic conditions that increase the risk of de novo malignancy following transplant. Patients often have more than one underlying liver disease, which could change the risk of de novo malignancy. This study assessed the incidence of NASH overlap and its effect on de novo malignancy in liver transplant recipients. Read More

View Article and Full-Text PDF

Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.

Med (N Y) 2021 Jul 27;2(7):800-813.e3. Epub 2021 Apr 27.

Pfizer Inc., Worldwide Research, Development, and Medicine, Cambridge, MA 02139, USA. Electronic address:

Background: Increased consumption of the lipogenic sugar fructose promotes the current epidemic of metabolic disease. Ketohexokinase (KHK) catalyzes the first committed step in fructose metabolism. In animal models, KHK inhibition decreases hepatic de novo lipogenesis and steatosis and corrects many metabolic abnormalities associated with insulin resistance. Read More

View Article and Full-Text PDF

Finding a sweet spot for leptin.

Med (N Y) 2021 Jul;2(7):794-796

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem that progresses to serious liver disease in some patients and for which there are no FDA-approved therapies. In this issue of Med, Akinci et al. present encouraging preliminary data showing that treatment with recombinant leptin has beneficial effects on NAFLD. Read More

View Article and Full-Text PDF

Insulin-Like Growth Factor-I Might be a Predictor for Severe Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients.

Horm Metab Res 2022 May 19. Epub 2022 May 19.

Endocrinology and Metabolism, University of Health Science Bakırköy Dr. Sadi Konuk Trining and Research Hospital, İstanbul, Turkey.

To compare the IGF-1 levels, metabolic and clinical parameters among the ultrasonographically classified non-alcoholic fatty liver disease (NAFLD) groups and determine the factors that may predict the NAFLD severity in patients with morbid obesity.This study was conducted on 316 morbidly obese patients (250 females, 66 males). The data of patients before and 1st-year after bariatric surgery were recorded. Read More

View Article and Full-Text PDF

Upregulation of 4-Hydroxynonenal Contributes to the Negative Effect of n-6 Polyunsaturated Fatty Acid on Alcohol-Induced Liver Injury and Hepatic Steatosis.

J Agric Food Chem 2022 May 19. Epub 2022 May 19.

School of Public Health, Zhejiang Chinese Medical University, Hangzhou 310013, China.

The present study aimed to investigate the effects of saturated fatty acids (SFA) and n-6 polyunsaturated fatty acids (PUFA) on alcoholic liver disease (ALD) and the underlying mechanisms. C57BL/6J male mice were randomly fed a corn oil or palm oil diet (rich in n-6 PUFA and SFA, respectively) with or without ethanol for four weeks ( = 10/group). A series of experiments in vitro with AML-12 hepatocyte were conducted to better elucidate the potential mechanisms underlying the phenomenon observed in animals. Read More

View Article and Full-Text PDF

Nonalcoholic Fatty Liver Disease and Accelerated Loss of Skeletal Muscle Mass: A Longitudinal Cohort Study.

Hepatology 2022 May 19. Epub 2022 May 19.

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Background And Aims: Whether subjects with non-alcoholic fatty liver disease (NAFLD) are at increased risk of sarcopenia is not well established.

Approach And Results: This is a cohort study of 52,815 men and women of 20 years of age or older who underwent at least 2 health check-up exams with bioelectrical impedance analysis and abdominal ultrasound imaging. Bioelectrical impedance analysis was used to calculate appendicular skeletal muscle mass (ASM). Read More

View Article and Full-Text PDF

Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals.

J Clin Endocrinol Metab 2022 May 19. Epub 2022 May 19.

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Background & Aims: Metabolic Associated Fatty Liver Disease (MAFLD) was proposed as a better definition of Non-Alcoholic Fatty Liver Disease (NAFLD) to encompass the metabolic dysregulation associated with NAFLD. This redefinition challenges our understanding of the disease. Hence, this study sought to conduct an updated analysis of the prevalence, clinical characteristics and associated factors of MAFLD, with a further sensitivity analysis done based on lean and non-obese MAFLD individuals. Read More

View Article and Full-Text PDF

Hepatocellular Cystathionine γ lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.

Hepatology 2022 May 19. Epub 2022 May 19.

Hypertension Center, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background & Aim: Hydrogen sulfide (H S) plays a protective role in non-alcoholic fatty liver disease (NAFLD). However, whether cystathionine gamma lyase (CSE), a dominant H S generating enzyme in hepatocytes, has a role in the pathogenesis of NAFLD is currently unclear.

Approach & Results: We showed that CSE protein expression is dramatically down-regulated, especially in fibrotic areas, in livers from NAFLD patients. Read More

View Article and Full-Text PDF

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice.

Front Pharmacol 2022 2;13:851342. Epub 2022 May 2.

Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.

Non-alcoholic fatty liver disease (NAFLD) is a widespread disease, but no recognized drug treatment exists. Previous studies have shown that artemether (Art) can ameliorate carbon tetrachloride (CCl)-induced liver fibrosis in mice. This study sets out to observe the therapeutic impact of Art on non-alcoholic steatohepatitis (NASH). Read More

View Article and Full-Text PDF

Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome.

Front Pharmacol 2022 2;13:851267. Epub 2022 May 2.

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Tiaoganquzhi Decoction (TGQZD) is a traditional Chinese herbal formulation demonstrated to be a clinically effective treatment for nonalcoholic fatty liver disease (NAFLD), although details concerning its clinical mechanism are poor. This study aimed to explore the mechanism of TGQZD on improvement of inflammatory damage and dyslipidemia caused by NAFLD through the CGI-58/ROS/NLRP3 inflammasome pathway. In our research, the protective effects of TGQZD on HFD-induced liver injury in rats and using lipopolysaccharide (LPS)+palmitate (PA)-stimulated HepG-2 cells model. Read More

View Article and Full-Text PDF

The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease.

Clin Mol Hepatol 2022 May 19. Epub 2022 May 19.

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is closely associated with diabetes. The cumulative impact of both diseases synergistically increases risk of adverse events. However, present population analysis is predominantly conducted with reference to non-NAFLD individuals and has not yet examined the impact of prediabetes. Read More

View Article and Full-Text PDF

Krüppel-like factors in glycolipid metabolic diseases.

Mol Biol Rep 2022 May 18. Epub 2022 May 18.

Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, 230032, Hefei, Anhui, China.

Krüppel-like factors (KLFs) are a family of transcription factors characterised by zinc-finger structures at the C-terminal. They play the key roles in cell proliferation, differentiation, and migration, as well as in embryonic development. They have been widely expressed in multiple systems in vivo, and their dysregulation is closely associated with a variety of human diseases. Read More

View Article and Full-Text PDF

Incremental levels of diagnostic information incentivize health-seeking in non-alcoholic fatty liver: a randomized clinical trial.

Sci Rep 2022 May 18;12(1):8272. Epub 2022 May 18.

Obesity and Digestive Diseases Unit and Translational Research Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150 Col. Toriello Guerra Tlalpan, 14050, Mexico City, Mexico.

Patients with chronic disorders like non-alcoholic fatty liver disease (NAFLD) face important challenges adhering to diagnostic and treatment tracks. As NAFLD increases, the need to incentivize health-seeking behaviors grows. No evidence-based interventions to address this gap exist. Read More

View Article and Full-Text PDF

Hepatocellular carcinoma versus nonalcoholic fatty liver disease: metabolic, environmental, and genetic association? De facto?

Rev Assoc Med Bras (1992) 2022 May;68(5):708-711

Inonu University, Faculty of Medicine, Department of Surgery, Liver Transplantation Institute - Malatya, Turkey.

View Article and Full-Text PDF

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats.

Braz J Med Biol Res 2022 16;55:e12096. Epub 2022 May 16.

College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Nonalcoholic fatty liver disease (NAFLD) is considered to be a manifestation of hepatic metabolic syndrome. Some studies on the pathogenesis of NAFLD by targeting gut microbiota have attracted wide attention. Previous studies have demonstrated the positive effects of berberine and evodiamine on metabolic diseases and gut microbiota dysbiosis. Read More

View Article and Full-Text PDF

Molecular Mechanism of Polysaccharides Extracted from Chinese Medicine Targeting Gut Microbiota for Promoting Health.

Chin J Integr Med 2022 May 18. Epub 2022 May 18.

Shandong Co-innovation Center of Classic Traditional Chinese Medicine Formula, Shandong University of Traditional Chinese Medicine, Ji'nan, 250355, China.

The accumulating evidence revealed that gut microbiota plays an important role in pathological process of disease including obesity, type 2 diabetes mellitus, heart failure, and non-alcoholic fatty liver disease. Polysaccharides extracted from Chinese medicine (CM) can not only alleviate pathological status but also promote health by anti-inflammatory, regulating immunity, lowering blood glucose and lipids, anti-cancer, and anti-oxidation. The alterations of gut microbiota composition and metabolism pathways are the potential mechanisms of CM polysaccharides treatment. Read More

View Article and Full-Text PDF

Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study.

World J Hepatol 2022 Mar;14(3):551-558

Department of Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.

Background: Non-alcoholic fatty liver disease (NAFLD) is currently considered as the most common cause of chronic liver disease worldwide. Risk factors for NAFLD have been well-described, including obesity, type 2 diabetes mellites (T2DM), dyslipidemia (DLP) and metabolic syndrome. Hypothyroidism has been identified as an independent risk factor for the development of NAFLD, although the literature is inconsistent. Read More

View Article and Full-Text PDF

Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.

World J Gastroenterol 2022 Apr;28(15):1563-1573

Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand.

Background: Identifying hepatic fibrosis is crucial for nonalcoholic fatty liver disease (NAFLD) management. The fibrosis-8 (FIB-8) score, recently developed by incorporating four additional variables into the fibrosis-4 (FIB-4) score, showed better performance in predicting significant fibrosis in NAFLD.

Aim: To validate the FIB-8 score in a biopsy-proven NAFLD cohort and compare the diagnostic performance of the FIB-8 and FIB-4 scores and NAFLD fibrosis score (NFS) for predicting significant fibrosis. Read More

View Article and Full-Text PDF

Comparison of reader agreement, correlation with liver biopsy, and time-burden sampling strategies for liver proton density fat fraction measured using magnetic resonance imaging in patients with obesity: a secondary cross-sectional study.

BMC Med Imaging 2022 May 17;22(1):92. Epub 2022 May 17.

Department of Radiology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.

Background: The magnetic resonance imaging (MRI)-based proton density fat fraction (PDFF) has become popular for quantifying liver fat content. However, the variability of the region-of-interest (ROI) sampling strategy may result in a lack of standardisation of this technology. In an effort to establish an accurate and effective PDFF measurement scheme, this study assessed the pathological correlation, the reader agreement, and time-burden of different sampling strategies with variable ROI size, location, and number. Read More

View Article and Full-Text PDF

Epidemiology and lifestyle survey of non-alcoholic fatty liver disease in school-age children and adolescents in Shenyang, Liaoning.

BMC Pediatr 2022 May 17;22(1):286. Epub 2022 May 17.

Gastroenterology Department, The First Affiliated Hospital of China Medical University, No.155 North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.

Background: Non-alcoholic fatty liver disease (NAFLD) is diagnosed increasingly in children and adolescents. We aimed to investigate the prevalence and related influencing factors of NAFLD in school-aged children and adolescents in Shenyang, Liaoning Province. Furthermore, we analyzed the relationship between lifestyle and fatty liver. Read More

View Article and Full-Text PDF

Dynamic human liver proteome atlas reveals functional insights into disease pathways.

Mol Syst Biol 2022 May;18(5):e10947

Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteome resource at cell type resolution to predict outcome and design therapy. Here, we quantify more than 150,000 sequence-unique peptides aggregated into 10,000 proteins across total liver, the major liver cell types, time course of primary cell cultures, and liver disease states. Bioinformatic analysis reveals that half of hepatocyte protein mass is comprised of enzymes and 23% of mitochondrial proteins, twice the proportion of other liver cell types. Read More

View Article and Full-Text PDF

Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases.

Compr Physiol 2022 Mar 29;12(2):3167-3192. Epub 2022 Mar 29.

Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

The increased production of derivatives of molecular oxygen and nitrogen in the form of reactive oxygen species (ROS) and reactive nitrogen species (RNS) lead to molecular damage called oxidative stress. Under normal physiological conditions, the ROS generation is tightly regulated in different cells and cellular compartments. Any disturbance in the balance between the cellular generation of ROS and antioxidant balance leads to oxidative stress. Read More

View Article and Full-Text PDF

Renal Artery Resistive Index and Estimated Glomerular Filtration Rate in Patients with Non-alcoholic Fatty Liver Disease.

Curr Med Imaging 2022 May 16. Epub 2022 May 16.

Kırşehir Ahi Evran University Medical Faculty,Department of Radiology, Kırşehir, Turkey.

Objectives: Non-alcoholic fatty liver disease [NAFLD], may affect many organs and systems, especially the kidney, as well as the liver. While NAFLD's renal impacts can be evaluated via the estimated glomerular filtration rate [eGFR], its effects on renal hemodynamic changes can be monitored with renal resistive index [RRI]. Our aim in this study is to evaluate RRI and eGFR in NAFLD patients. Read More

View Article and Full-Text PDF

Corrigendum to "Amelioration action of gastrodigenin rhamno-pyranoside from Moringa seeds on non-alcoholic fatty liver disease" [Food Chem. 379 (2022) 132087].

Food Chem 2022 May 13:133166. Epub 2022 May 13.

Laboratory of Drug Delivery and Tissue Regeneration, Jiangsu Provincial Research Center for Medicinal Function Development of New Food Resources, School of Pharmacy, Jiangsu University, Zhenjiang 212013, PR China. Electronic address:

View Article and Full-Text PDF

Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo.

J Ethnopharmacol 2022 May 13:115382. Epub 2022 May 13.

The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, Jiangsu, China; Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China. Electronic address:

Ethnopharmacological Relevance: Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear.

Aim Of The Study: We evaluated the effects and mechanisms of JPQGY and hepatic steatosis caused by the middle stage of 13-week-high-fat-diet-induced NAFLD in mice.

Materials And Methods: Different dosages of JPQGY (5. Read More

View Article and Full-Text PDF